Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302
February 26, 2025 07:30 ET
|
Quantum BioPharma
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302
Quantum BioPharma Continues to Diversify its Treasury with the Purchase of Another USD $1,000,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
February 18, 2025 07:30 ET
|
Quantum BioPharma
Quantum BioPharma Continues to Diversify its Treasury with the Purchase of Another USD $1,000,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
February 11, 2025 07:30 ET
|
Quantum BioPharma
Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs
February 10, 2025 07:30 ET
|
Quantum BioPharma
Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs
Quantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical Study
February 06, 2025 07:30 ET
|
Quantum BioPharma
QUANTUM BIOPHARMA PARTNER CELLY NUTRITION RETAINS LEADING NEW YORK INVESTMENT BANK TO ADVISE ON CAPITAL RAISE AND POSSIBLE INITIAL PUBLIC OFFERING FOLLOWIN
Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial
February 04, 2025 07:03 ET
|
Quantum BioPharma
TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company...
Quantum BioPharma Diversifies Treasury with the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency
December 20, 2024 07:30 ET
|
Quantum BioPharma
TORONTO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval...